1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Alzheimer’s Therapeutics Market, By Product
5.1 Introduction
5.2 Cholinesterase Inhibitors
5.2.1 Donepezil
5.2.2 Rivastigmine
5.2.3 Galantamine
5.3 N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
5.4 Combination Drug
5.5 Other Products
6 Global Alzheimer’s Therapeutics Market, By End User
6.1 Introduction
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Drug Stores
6.5 Online Pharmacies
6.6 Other End Users
7 Global Alzheimer’s Therapeutics Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Cipla Ltd.
9.2 Daiichi Sankyo Company, Limited
9.3 Dr. Reddy’s Laboratories Ltd
9.4 Amneal Pharmaceuticals Inc.
9.5 Aurobindo Pharma Ltd
9.6 AbbVie, Inc.
9.7 Eisai Co., Ltd.
9.8 Adamas Pharmaceuticals, Inc.
9.9 F. Hoffmann La Roche Ltd.
9.10 H. Lundbeck A/S
9.11 Johnson & Johnson Services, Inc.
9.12 Novartis AG
9.13 Sun Pharmaceutical Industries Ltd.
9.14 TauRx Pharmaceuticals Ltd.
9.15 Lannett Inc.
9.16 Lupin Ltd
9.17 Macleods Pharmaceuticals Ltd.
List of Tables
Table 1 Global Alzheimer’s Therapeutics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 4 Global Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 5 Global Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 6 Global Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 7 Global Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 8 Global Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 9 Global Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 10 Global Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 11 Global Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 12 Global Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 13 Global Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 14 Global Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 15 Global Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 16 North America Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 17 North America Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 18 North America Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 19 North America Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 20 North America Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 21 North America Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 22 North America Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 23 North America Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 24 North America Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 25 North America Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 26 North America Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 27 North America Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 28 North America Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 29 North America Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 30 North America Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 31 Europe Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 32 Europe Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 33 Europe Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 34 Europe Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 35 Europe Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 36 Europe Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 37 Europe Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 38 Europe Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 39 Europe Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 40 Europe Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 41 Europe Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 42 Europe Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 43 Europe Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 44 Europe Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 45 Europe Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 46 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 47 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 48 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 49 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 50 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 51 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 52 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 53 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 54 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 55 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 56 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 57 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 58 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 59 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 60 Asia Pacific Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 61 South America Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 62 South America Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 63 South America Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 64 South America Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 65 South America Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 66 South America Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 67 South America Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 68 South America Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 69 South America Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 70 South America Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 71 South America Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 72 South America Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 73 South America Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 74 South America Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 75 South America Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 77 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 78 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
Table 79 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
Table 80 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
Table 81 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
Table 82 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
Table 83 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 84 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 85 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By End User (2021-2030) ($MN)
Table 86 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 87 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 88 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 89 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 90 Middle East & Africa Alzheimer’s Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
| ※参考情報 アルツハイマー治療薬は、アルツハイマー病に関連する症状を緩和することを目的とした薬剤です。アルツハイマー病は、神経細胞の変性や死滅が進行することで記憶や思考能力が低下する進行性の認知症の一つです。治療薬は、主に症状の進行を遅らせることを目的に開発されています。 アルツハイマー治療薬にはいくつかの種類があります。代表的なものとして、コリンエステラーゼ阻害薬とNMDA受容体拮抗薬があります。コリンエステラーゼ阻害薬は、アセチルコリンという神経伝達物質の分解を抑制することにより、脳内のアセチルコリン濃度を高め、神経の伝達を改善します。これにより、認知機能が一時的に改善されることがあります。具体的には、ドネペジル、リバスチグミン、ガランタミンなどがこのクラスの薬剤です。 一方、NMDA受容体拮抗薬は、グルタミン酸に対する受容体を抑制することによって、神経細胞の過剰な興奮を防ぎます。これにより、神経細胞へのダメージを軽減し、病状の進行を遅らせることが期待されています。メマンチンはこのクラスに属する薬剤です。 具体的な用途としては、これらの治療薬は主に中等度から重度のアルツハイマー病患者に対して処方されています。早期の段階では、非薬物的な治療法や支援が重要ですが、病状が進行するにつれて薬物療法が必要となる場合があります。患者によって反応は異なるため、適切な治療法を見つけることが求められます。 最近では、アルツハイマー病に対する新しい治療アプローチも研究されています。特に、抗アミロイドβ抗体薬やタウ蛋白に対する治療薬の開発が進んでいます。これらの薬剤は、アルツハイマー病の病因に関連する構造物、すなわちアミロイドプラークやタウの異常蓄積をターゲットにしています。アデュカヌマブやラナブタムマブなどの新薬は、これらのメカニズムに基づいており、投与により顕著な効果が示されることがあります。これらの新しい治療法は、従来の薬剤に比べて病気の進行を抑制する可能性があるため、多くの期待が寄せられています。 また、アルツハイマー病の治療に関連する技術としては、早期診断やモニタリングシステムの研究が進んでいます。脳画像技術の進歩により、アミロイドβやタウタンパク質の蓄積を前もって確認することができるようになっています。さらに、バイオマーカーを用いた血液検査の開発も進展しており、これによりより早い段階での病気の検出が期待されています。このような技術は、将来の治療戦略にとって重要な役割を果たすと考えられています。 最後に、アルツハイマー治療薬はあくまで症状の管理の一環であるため、薬物治療だけでなく、生活習慣の改善や家族・社会からのサポートも不可欠です。非薬物療法としては、認知トレーニングや運動療法、栄養管理が推奨されています。患者自身とその周囲の人々が協力して、質の高い生活を維持することが、アルツハイマー病の進行を遅らせる鍵となります。アルツハイマー治療薬の研究は今後も続き、より効果的な治療法の確立を目指していくことが重要です。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
